Experimental GLP-1 pill achieves up to 12% weight loss in 36 weeks
Aleniglipron, a new oral molecule, shows promising results in a clinical study.
An experimental tablet acting as a GLP-1 receptor agonist demonstrated, in a study, weight loss of up to 12.1% of body weight over a 36‑week period. The compound, named aleniglipron, was tested in participants with obesity or overweight.
Differentiation from injectable medicines
Unlike known injectable therapies such as Wegovy and Ozempic, aleniglipron is a small molecule that can be taken orally once daily, regardless of food intake. This characteristic may facilitate large‑scale production.
How GLP-1 agonists work
GLP-1 agonists are a class of drugs that, by stimulating the glucagon‑like peptide‑1 receptor, increase satiety and reduce caloric intake. This mechanism has been explored in various approaches for weight control and glycemia management.
Future outlook
The result of up to 12.1% weight loss in 36 weeks suggests that an oral formulation could represent a practical alternative to current treatment. However, the compound is still in the experimental phase and requires further evaluation before being considered for widespread clinical use.
With information from ScienceDaily.
Source: ScienceDaily